PL3389727T3 - RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET - Google Patents
RADIOZNAKOWANE LIGANDY mGluR2/3 DO PETInfo
- Publication number
- PL3389727T3 PL3389727T3 PL16812961T PL16812961T PL3389727T3 PL 3389727 T3 PL3389727 T3 PL 3389727T3 PL 16812961 T PL16812961 T PL 16812961T PL 16812961 T PL16812961 T PL 16812961T PL 3389727 T3 PL3389727 T3 PL 3389727T3
- Authority
- PL
- Poland
- Prior art keywords
- pet ligands
- mglur2
- radiolabelled
- radiolabelled mglur2
- ligands
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15201240 | 2015-12-18 | ||
| EP16812961.7A EP3389727B1 (en) | 2015-12-18 | 2016-12-16 | Radiolabelled mglur2/3 pet ligands |
| PCT/EP2016/081542 WO2017103182A1 (en) | 2015-12-18 | 2016-12-16 | Radiolabelled mglur2/3 pet ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3389727T3 true PL3389727T3 (pl) | 2021-02-08 |
Family
ID=55023944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16812961T PL3389727T3 (pl) | 2015-12-18 | 2016-12-16 | RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11033641B2 (pl) |
| EP (1) | EP3389727B1 (pl) |
| JP (1) | JP6927974B2 (pl) |
| AU (1) | AU2016374571B2 (pl) |
| CA (1) | CA3003998A1 (pl) |
| CY (1) | CY1124935T1 (pl) |
| DK (1) | DK3389727T3 (pl) |
| ES (1) | ES2828976T3 (pl) |
| HR (1) | HRP20201372T1 (pl) |
| HU (1) | HUE050665T2 (pl) |
| LT (1) | LT3389727T (pl) |
| PL (1) | PL3389727T3 (pl) |
| PT (1) | PT3389727T (pl) |
| RS (1) | RS60981B1 (pl) |
| SI (1) | SI3389727T1 (pl) |
| SM (1) | SMT202000591T1 (pl) |
| WO (1) | WO2017103182A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| WO2016087487A1 (en) | 2014-12-03 | 2016-06-09 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| ES2727158T3 (es) | 2014-12-03 | 2019-10-14 | Janssen Pharmaceutica Nv | Ligandos para PET de mGluR2 radiomarcados |
| JP6927974B2 (ja) | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド |
| CA3003962A1 (en) | 2015-12-18 | 2017-06-22 | Janssen Pharmaceutica Nv | Radiolabelled mglur2/3 pet ligands |
| JP7242548B2 (ja) | 2017-11-24 | 2023-03-20 | 住友ファーマ株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0756200B1 (en) | 1995-07-26 | 1999-11-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6831074B2 (en) | 2001-03-16 | 2004-12-14 | Pfizer Inc | Pharmaceutically active compounds |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| WO2005061507A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof |
| DE602005004287T2 (de) | 2004-06-21 | 2008-12-24 | F. Hoffmann-La Roche Ag | Pyrrazolopyrimidinderivate |
| WO2006030847A1 (ja) | 2004-09-17 | 2006-03-23 | Dainippon Sumitomo Pharma Co., Ltd. | 新規二環性ピラゾール誘導体 |
| DE102004054665A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| WO2006084634A1 (en) | 2005-02-11 | 2006-08-17 | F.Hoffmann-La Roche Ag | Pyrazolo-pyrimidine derivatives as mglur2 antagonists |
| SI1863818T1 (sl) | 2005-03-23 | 2010-05-31 | Hoffmann La Roche | Derivati acetilenil pirazolo pirimidina kot antagonisti mglur |
| US7998959B2 (en) | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| WO2008141249A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2085390A1 (en) | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| WO2009130232A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| EP2327704A4 (en) | 2008-08-29 | 2012-05-09 | Shionogi & Co | RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT |
| CN102143955B (zh) | 2008-09-02 | 2013-08-14 | Omj制药公司 | 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| WO2012062752A1 (en) * | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | RADIOLABELLED mGLuR2 PET LIGANDS |
| JP2013545822A (ja) | 2010-12-17 | 2013-12-26 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ５受容体のアロステリック調節剤としての、二環式トリアゾールラクタムおよびピラゾールラクタム |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20140088887A (ko) | 2011-11-03 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도 |
| JP2013189395A (ja) | 2012-03-14 | 2013-09-26 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロピロロピラジノン誘導体 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| US20130345204A1 (en) | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| US20130345205A1 (en) | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| CN104736156A (zh) | 2012-06-20 | 2015-06-24 | 范德比尔特大学 | 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物 |
| CA2877999C (en) | 2012-07-03 | 2021-02-23 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| WO2014064028A1 (en) | 2012-10-23 | 2014-05-01 | F. Hoffmann-La Roche Ag | Mglu2/3 antagonists for the treatment of autistic disorders |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| BR122023004130B1 (pt) | 2013-06-27 | 2023-12-12 | Pfizer Inc | Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1 |
| CN105473592B (zh) | 2013-06-27 | 2018-10-26 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物 |
| CA2954222C (en) | 2014-08-01 | 2022-11-29 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JO3601B1 (ar) * | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| US10220032B2 (en) | 2014-08-01 | 2019-03-05 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| WO2016087487A1 (en) | 2014-12-03 | 2016-06-09 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| ES2727158T3 (es) | 2014-12-03 | 2019-10-14 | Janssen Pharmaceutica Nv | Ligandos para PET de mGluR2 radiomarcados |
| JP2016124810A (ja) * | 2014-12-26 | 2016-07-11 | 大日本住友製薬株式会社 | 新規縮合ピラゾール誘導体およびその医薬用途 |
| CA3003962A1 (en) | 2015-12-18 | 2017-06-22 | Janssen Pharmaceutica Nv | Radiolabelled mglur2/3 pet ligands |
| JP6927974B2 (ja) | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド |
-
2016
- 2016-12-16 JP JP2018531628A patent/JP6927974B2/ja not_active Expired - Fee Related
- 2016-12-16 AU AU2016374571A patent/AU2016374571B2/en not_active Ceased
- 2016-12-16 RS RS20201288A patent/RS60981B1/sr unknown
- 2016-12-16 EP EP16812961.7A patent/EP3389727B1/en active Active
- 2016-12-16 SM SM20200591T patent/SMT202000591T1/it unknown
- 2016-12-16 US US16/061,437 patent/US11033641B2/en not_active Expired - Fee Related
- 2016-12-16 WO PCT/EP2016/081542 patent/WO2017103182A1/en active Application Filing
- 2016-12-16 PL PL16812961T patent/PL3389727T3/pl unknown
- 2016-12-16 SI SI201630916T patent/SI3389727T1/sl unknown
- 2016-12-16 LT LTEP16812961.7T patent/LT3389727T/lt unknown
- 2016-12-16 DK DK16812961.7T patent/DK3389727T3/da active
- 2016-12-16 ES ES16812961T patent/ES2828976T3/es active Active
- 2016-12-16 CA CA3003998A patent/CA3003998A1/en active Pending
- 2016-12-16 HR HRP20201372TT patent/HRP20201372T1/hr unknown
- 2016-12-16 PT PT168129617T patent/PT3389727T/pt unknown
- 2016-12-16 HU HUE16812961A patent/HUE050665T2/hu unknown
-
2020
- 2020-11-09 CY CY20201101051T patent/CY1124935T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3389727T3 (da) | 2020-11-02 |
| US20200306389A1 (en) | 2020-10-01 |
| HRP20201372T1 (hr) | 2020-11-27 |
| ES2828976T3 (es) | 2021-05-28 |
| SMT202000591T1 (it) | 2020-11-10 |
| CA3003998A1 (en) | 2017-06-22 |
| WO2017103182A1 (en) | 2017-06-22 |
| HUE050665T2 (hu) | 2020-12-28 |
| AU2016374571B2 (en) | 2021-05-06 |
| SI3389727T1 (sl) | 2020-10-30 |
| AU2016374571A1 (en) | 2018-05-17 |
| EP3389727A1 (en) | 2018-10-24 |
| US11033641B2 (en) | 2021-06-15 |
| CY1124935T1 (el) | 2022-07-22 |
| JP2019502700A (ja) | 2019-01-31 |
| EP3389727B1 (en) | 2020-08-12 |
| RS60981B1 (sr) | 2020-11-30 |
| JP6927974B2 (ja) | 2021-09-01 |
| PT3389727T (pt) | 2020-10-30 |
| LT3389727T (lt) | 2020-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201507594D0 (en) | Intamac 1 | |
| IL259966B (en) | Radiolabelled mglur2/3 pet ligands | |
| GB201521134D0 (en) | Privitar case 1 | |
| SMT202000591T1 (it) | Ligandi pet radiomarcati mglur 2/3 | |
| GB201513478D0 (en) | Pet hideaways | |
| AU5457P (en) | JOAe 6656 Aeonium arborium | |
| GB201521156D0 (en) | Concept 80 | |
| GB201521164D0 (en) | Concept 85 | |
| GB201521163D0 (en) | Concept 78 | |
| GB201521158D0 (en) | Concept 82 | |
| GB201521157D0 (en) | Concept 74 | |
| GB201505171D0 (en) | Concept 37 | |
| GB201505192D0 (en) | Concept 46 | |
| GB201505149D0 (en) | Concept 31 | |
| GB201505154D0 (en) | Concept 22 | |
| GB201505186D0 (en) | Concept 51 | |
| GB201505188D0 (en) | Concept 47 | |
| GB201505155D0 (en) | Concept 21 | |
| GB201505183D0 (en) | Concept 52 | |
| GB201505147D0 (en) | Concept 33 | |
| GB201505180D0 (en) | Concept 53 | |
| GB201505179D0 (en) | Concept 54 | |
| GB201505175D0 (en) | Concept 40 | |
| GB201505174D0 (en) | Concept 40 | |
| GB201505153D0 (en) | Concept 23 |